America's first

exclusively orphan
drug company

America's first

exclusively orphan
drug company

America's first exclusively orphan drug company

Pioneers in commercializing orphan drugs since 1991

A unique combination of commercialization services for rare disease treatments

We have helped bring life-saving and life-extending treatments to people with unmet medical needs for over 30 years.

As America’s first exclusively orphan drug company, we have expertise in regulatory affairs, sales and marketing, and medical affairs – with a proven track record of success in bringing orphan drugs through the FDA approval process.


RDT isn’t “Big Pharma.” We are a privately held, specialized company that moves quickly and efficiently to meet patient needs. We have pride in our skill and efficiency in bringing orphan drugs to market:

  • A wealth of regulatory experience in navigating orphan drug INDs, BLAs, and NDAs*
  • Precisely targeted sales and marketing strategies for rare disease treatments
  • Vast medical knowledge in clinical research and development for rare disease treatments

Now, that’s rare.

Helping Patients

See our current portfolio of rare disease treatments alongside our pipeline of future offerings

Corporate Partnership

Pharmaceutical companies with orphan drugs in development can utilize our commercialization services

Rare Individuals

The expertise within RDT makes us a unique orphan drug company and commercialization partner

* IND = Investigational New Drug Application, BLA =  Biologics License Application, NDA = New Drug Application